1	Apoptosis	Apoptosis	_	_	_	_	_	_	_
2	and	and	_	_	_	_	_	_	_
3	growth	growth	_	_	_	_	_	_	_
4	inhibition	inhibition	_	_	_	_	_	_	_
5	in	in	_	_	_	_	_	_	_
6	malignant	malignant	_	_	_	_	_	_	_
7	lymphocytes	lymphocyte	_	_	_	_	_	_	_
8	after	after	_	_	_	_	_	_	_
9	treatment	treatment	_	_	_	_	_	_	_
10	with	with	_	_	_	_	_	_	_
11	arsenic	arsenic	_	_	_	_	_	_	_
12	trioxide	trioxide	_	_	_	_	_	_	_
13	at	at	_	_	_	_	_	_	_
14	clinically	clinically	_	_	_	_	_	_	_
15	achievable	achievable	_	_	_	_	_	_	_
16	concentrations	concentration	_	_	_	_	_	_	_
17	[	[	_	_	_	_	_	_	_
18	see	see	_	_	_	_	_	_	_
19	comments	comment	_	_	_	_	_	_	_
20	]	]	_	_	_	_	_	_	_
21	BACKGROUND	BACKGROUND	_	_	_	_	_	_	_
22	:	:	_	_	_	_	_	_	_
23	Arsenic	arsenic	_	_	_	_	_	_	_
24	trioxide	trioxide	_	_	_	_	_	_	_
25	(	(	_	_	_	_	_	_	_
26	As2O3	as2o3	_	_	_	_	_	_	_
27	)	)	_	_	_	_	_	_	_
28	can	can	_	_	_	_	_	_	_
29	induce	induce	_	_	_	_	_	_	_
30	clinical	clinical	_	_	_	_	_	_	_
31	remission	remission	_	_	_	_	_	_	_
32	in	in	_	_	_	_	_	_	_
33	patients	patient	_	_	_	_	_	_	_
34	with	with	_	_	_	_	_	_	_
35	acute	acute	_	_	_	_	_	_	_
36	promyelocytic	promyelocytic	_	_	_	_	_	_	_
37	leukemia	leukemia	_	_	_	_	_	_	_
38	via	via	_	_	_	_	_	_	_
39	induction	induction	_	_	_	_	_	_	_
40	of	of	_	_	_	_	_	_	_
41	differentiation	differentiation	_	_	_	_	_	_	_
42	and	and	_	_	_	_	_	_	_
43	programmed	program	_	_	_	_	_	_	_
44	cell	cell	_	_	_	_	_	_	_
45	death	death	_	_	_	_	_	_	_
46	(	(	_	_	_	_	_	_	_
47	apoptosis	apoptosis	_	_	_	_	_	_	_
48	)	)	_	_	_	_	_	_	_
49	.	.	_	_	_	_	_	_	_

1	We	we	_	_	_	_	_	_	_
2	investigated	investigate	_	_	_	_	_	_	_
3	the	the	_	_	_	_	_	_	_
4	effects	effect	_	_	_	_	_	_	_
5	of	of	_	_	_	_	_	_	_
6	As2O3	as2o3	_	_	_	_	_	_	_
7	on	on	_	_	_	_	_	_	_
8	a	a	_	_	_	_	_	_	_
9	panel	panel	_	_	_	_	_	_	_
10	of	of	_	_	_	_	_	_	_
11	malignant	malignant	_	_	_	_	_	_	_
12	lymphocytes	lymphocyte	_	_	_	_	_	_	_
13	to	to	_	_	_	_	_	_	_
14	determine	determine	_	_	_	_	_	_	_
15	whether	whether	_	_	_	_	_	_	_
16	growth-inhibitory	growth-inhibitory	_	_	_	_	_	_	_
17	and	and	_	_	_	_	_	_	_
18	apoptotic	apoptotic	_	_	_	_	_	_	_
19	effects	effect	_	_	_	_	_	_	_
20	of	of	_	_	_	_	_	_	_
21	As2O3	As2O3	_	_	_	_	_	_	_
22	can	can	_	_	_	_	_	_	_
23	be	be	_	_	_	_	_	_	_
24	observed	observe	_	_	_	_	_	_	_
25	in	in	_	_	_	_	_	_	_
26	these	these	_	_	_	_	_	_	_
27	cells	cell	_	_	_	_	_	_	_
28	at	at	_	_	_	_	_	_	_
29	clinically	clinically	_	_	_	_	_	_	_
30	achievable	achievable	_	_	_	_	_	_	_
31	concentrations	concentration	_	_	_	_	_	_	_
32	.	.	_	_	_	_	_	_	_

1	METHODS	methods	_	_	_	_	_	_	_
2	:	:	_	_	_	_	_	_	_
3	Eight	eight	_	_	_	_	_	_	_
4	malignant	malignant	_	_	_	_	_	_	_
5	lymphocytic	lymphocytic	_	_	_	_	_	_	_
6	cell	cell	_	_	_	_	_	_	_
7	lines	line	_	_	_	_	_	_	_
8	and	and	_	_	_	_	_	_	_
9	primary	primary	_	_	_	_	_	_	_
10	cultures	culture	_	_	_	_	_	_	_
11	of	of	_	_	_	_	_	_	_
12	lymphocytic	lymphocytic	_	_	_	_	_	_	_
13	leukemia	leukemia	_	_	_	_	_	_	_
14	and	and	_	_	_	_	_	_	_
15	lymphoma	lymphoma	_	_	_	_	_	_	_
16	cells	cell	_	_	_	_	_	_	_
17	were	be	_	_	_	_	_	_	_
18	treated	treat	_	_	_	_	_	_	_
19	with	with	_	_	_	_	_	_	_
20	As2O3	As2O3	_	_	_	_	_	_	_
21	,	,	_	_	_	_	_	_	_
22	with	with	_	_	_	_	_	_	_
23	or	or	_	_	_	_	_	_	_
24	without	without	_	_	_	_	_	_	_
25	dithiothreitol	dithiothreitol	_	_	_	_	_	_	_
26	(	(	_	_	_	_	_	_	_
27	DTT	DTT	_	_	_	_	_	_	_
28	)	)	_	_	_	_	_	_	_
29	or	or	_	_	_	_	_	_	_
30	buthionine	buthionine	_	_	_	_	_	_	_
31	sulfoximine	sulfoximine	_	_	_	_	_	_	_
32	(	(	_	_	_	_	_	_	_
33	BSO	BSO	_	_	_	_	_	_	_
34	)	)	_	_	_	_	_	_	_
35	(	(	_	_	_	_	_	_	_
36	an	an	_	_	_	_	_	_	_
37	inhibitor	inhibitor	_	_	_	_	_	_	_
38	of	of	_	_	_	_	_	_	_
39	glutathione	glutathione	_	_	_	_	_	_	_
40	synthesis	synthesis	_	_	_	_	_	_	_
41	)	)	_	_	_	_	_	_	_
42	.	.	_	_	_	_	_	_	_

1	Apoptosis	Apoptosis	_	_	_	_	_	_	_
2	was	be	_	_	_	_	_	_	_
3	assessed	assess	_	_	_	_	_	_	_
4	by	by	_	_	_	_	_	_	_
5	cell	cell	_	_	_	_	_	_	_
6	morphology	morphology	_	_	_	_	_	_	_
7	,	,	_	_	_	_	_	_	_
8	flow	flow	_	_	_	_	_	_	_
9	cytometry	cytometry	_	_	_	_	_	_	_
10	,	,	_	_	_	_	_	_	_
11	annexin	annexin	_	_	_	_	_	_	_
12	V	V	_	_	_	_	_	_	_
13	protein	protein	_	_	_	_	_	_	_
14	level	level	_	_	_	_	_	_	_
15	,	,	_	_	_	_	_	_	_
16	and	and	_	_	_	_	_	_	_
17	terminal	terminal	_	_	_	_	_	_	_
18	deoxynucleotidyl	deoxynucleotidyl	_	_	_	_	_	_	_
19	transferase	transferase	_	_	_	_	_	_	_
20	labeling	labeling	_	_	_	_	_	_	_
21	of	of	_	_	_	_	_	_	_
22	DNA	dna	_	_	_	_	_	_	_
23	fragments	fragment	_	_	_	_	_	_	_
24	.	.	_	_	_	_	_	_	_

1	Cellular	cellular	_	_	_	_	_	_	_
2	proliferation	proliferation	_	_	_	_	_	_	_
3	was	be	_	_	_	_	_	_	_
4	determined	determine	_	_	_	_	_	_	_
5	by	by	_	_	_	_	_	_	_
6	5-bromo-2â€™-deoxyuridine	5-bromo-2'-deoxyuridine	_	_	_	_	_	_	_
7	incorporation	incorporation	_	_	_	_	_	_	_
8	into	into	_	_	_	_	_	_	_
9	DNA	dna	_	_	_	_	_	_	_
10	and	and	_	_	_	_	_	_	_
11	flow	flow	_	_	_	_	_	_	_
12	cytometry	cytometry	_	_	_	_	_	_	_
13	and	and	_	_	_	_	_	_	_
14	by	by	_	_	_	_	_	_	_
15	use	use	_	_	_	_	_	_	_
16	of	of	_	_	_	_	_	_	_
17	a	a	_	_	_	_	_	_	_
18	mitotic	mitotic	_	_	_	_	_	_	_
19	arrest	arrest	_	_	_	_	_	_	_
20	assay	assay	_	_	_	_	_	_	_
21	.	.	_	_	_	_	_	_	_

1	Mitochondrial	mitochondrial	_	_	_	_	_	_	_
2	transmembrane	transmembrane	_	_	_	_	_	_	_
3	potential	potential	_	_	_	_	_	_	_
4	(	(	_	_	_	_	_	_	_
5	delta	delta	_	_	_	_	_	_	_
6	psi(m))	psi(m))	_	_	_	_	_	_	_
7	was	be	_	_	_	_	_	_	_
8	measured	measure	_	_	_	_	_	_	_
9	by	by	_	_	_	_	_	_	_
10	means	mean	_	_	_	_	_	_	_
11	of	of	_	_	_	_	_	_	_
12	rhodamine	rhodamine	_	_	_	_	_	_	_
13	123	123	_	_	_	_	_	_	_
14	staining	staining	_	_	_	_	_	_	_
15	and	and	_	_	_	_	_	_	_
16	flow	flow	_	_	_	_	_	_	_
17	cytometry	cytometry	_	_	_	_	_	_	_
18	.	.	_	_	_	_	_	_	_

1	Protein	protein	_	_	_	_	_	_	_
2	expression	expression	_	_	_	_	_	_	_
3	was	be	_	_	_	_	_	_	_
4	assessed	assess	_	_	_	_	_	_	_
5	by	by	_	_	_	_	_	_	_
6	western	western	_	_	_	_	_	_	_
7	blot	blot	_	_	_	_	_	_	_
8	analysis	analysis	_	_	_	_	_	_	_
9	or	or	_	_	_	_	_	_	_
10	immunofluorescence	immunofluorescence	_	_	_	_	_	_	_
11	.	.	_	_	_	_	_	_	_

1	RESULTS	results	_	_	_	_	_	_	_
2	:	:	_	_	_	_	_	_	_
3	Therapeutic	therapeutic	_	_	_	_	_	_	_
4	concentrations	concentration	_	_	_	_	_	_	_
5	of	of	_	_	_	_	_	_	_
6	As2O3	As2O3	_	_	_	_	_	_	_
7	(	(	_	_	_	_	_	_	_
8	1-2	1-2	_	_	_	_	_	_	_
9	microM	microM	_	_	_	_	_	_	_
10	)	)	_	_	_	_	_	_	_
11	had	have	_	_	_	_	_	_	_
12	dual	dual	_	_	_	_	_	_	_
13	effects	effect	_	_	_	_	_	_	_
14	on	on	_	_	_	_	_	_	_
15	malignant	malignant	_	_	_	_	_	_	_
16	lymphocytes	lymphocyte	_	_	_	_	_	_	_
17	:	:	_	_	_	_	_	_	_
18	1	1	_	_	_	_	_	_	_
19	)	)	_	_	_	_	_	_	_
20	inhibition	inhibition	_	_	_	_	_	_	_
21	of	of	_	_	_	_	_	_	_
22	growth	growth	_	_	_	_	_	_	_
23	through	through	_	_	_	_	_	_	_
24	adenosine	adenosine	_	_	_	_	_	_	_
25	triphosphate	triphosphate	_	_	_	_	_	_	_
26	(	(	_	_	_	_	_	_	_
27	ATP	ATP	_	_	_	_	_	_	_
28	)	)	_	_	_	_	_	_	_
29	depletion	depletion	_	_	_	_	_	_	_
30	and	and	_	_	_	_	_	_	_
31	prolongation	prolongation	_	_	_	_	_	_	_
32	of	of	_	_	_	_	_	_	_
33	cell	cell	_	_	_	_	_	_	_
34	cycle	cycle	_	_	_	_	_	_	_
35	time	time	_	_	_	_	_	_	_
36	and	and	_	_	_	_	_	_	_
37	2	2	_	_	_	_	_	_	_
38	)	)	_	_	_	_	_	_	_
39	induction	induction	_	_	_	_	_	_	_
40	of	of	_	_	_	_	_	_	_
41	apoptosis	apoptosis	_	_	_	_	_	_	_
42	.	.	_	_	_	_	_	_	_

1	As2O3-induced	as2o3-induced	_	_	_	_	_	_	_
2	apoptosis	apoptosis	_	_	_	_	_	_	_
3	was	be	_	_	_	_	_	_	_
4	preceded	precede	_	_	_	_	_	_	_
5	by	by	_	_	_	_	_	_	_
6	delta	delta	_	_	_	_	_	_	_
7	psi(m)	psi(m)	_	_	_	_	_	_	_
8	collapse	collapse	_	_	_	_	_	_	_
9	.	.	_	_	_	_	_	_	_

1	DTT	DTT	_	_	_	_	_	_	_
2	antagonized	antagonize	_	_	_	_	_	_	_
3	and	and	_	_	_	_	_	_	_
4	BSO	bso	_	_	_	_	_	_	_
5	enhanced	enhance	_	_	_	_	_	_	_
6	As2O3-induced	as2o3-induced	_	_	_	_	_	_	_
7	ATP	ATP	_	_	_	_	_	_	_
8	depletion	depletion	_	_	_	_	_	_	_
9	,	,	_	_	_	_	_	_	_
10	delta	delta	_	_	_	_	_	_	_
11	psi(m)	psi(m)	_	_	_	_	_	_	_
12	collapse	collapse	_	_	_	_	_	_	_
13	,	,	_	_	_	_	_	_	_
14	and	and	_	_	_	_	_	_	_
15	apoptosis	apoptosis	_	_	_	_	_	_	_
16	.	.	_	_	_	_	_	_	_

1	Caspase-3	caspase-3	_	_	_	_	_	_	_
2	activation	activation	_	_	_	_	_	_	_
3	,	,	_	_	_	_	_	_	_
4	usually	usually	_	_	_	_	_	_	_
5	resulting	result	_	_	_	_	_	_	_
6	from	from	_	_	_	_	_	_	_
7	delta	delta	_	_	_	_	_	_	_
8	psi(m)	psi(m)	_	_	_	_	_	_	_
9	collapse	collapse	_	_	_	_	_	_	_
10	,	,	_	_	_	_	_	_	_
11	was	be	_	_	_	_	_	_	_
12	not	not	_	_	_	_	_	_	_
13	always	always	_	_	_	_	_	_	_
14	associated	associate	_	_	_	_	_	_	_
15	with	with	_	_	_	_	_	_	_
16	As2O3-induced	as2o3-induced	_	_	_	_	_	_	_
17	apoptosis	apoptosis	_	_	_	_	_	_	_
18	.	.	_	_	_	_	_	_	_

1	As2O3	As2O3	_	_	_	_	_	_	_
2	induced	induce	_	_	_	_	_	_	_
3	PML	PML	_	_	_	_	_	_	_
4	(	(	_	_	_	_	_	_	_
5	promyelocytic	promyelocytic	_	_	_	_	_	_	_
6	leukemia	leukemia	_	_	_	_	_	_	_
7	)	)	_	_	_	_	_	_	_
8	protein	protein	_	_	_	_	_	_	_
9	degradation	degradation	_	_	_	_	_	_	_
10	but	but	_	_	_	_	_	_	_
11	did	do	_	_	_	_	_	_	_
12	not	not	_	_	_	_	_	_	_
13	modulate	modulate	_	_	_	_	_	_	_
14	expression	expression	_	_	_	_	_	_	_
15	of	of	_	_	_	_	_	_	_
16	cell	cell	_	_	_	_	_	_	_
17	cycle-related	cycle-related	_	_	_	_	_	_	_
18	proteins	protein	_	_	_	_	_	_	_
19	,	,	_	_	_	_	_	_	_
20	including	include	_	_	_	_	_	_	_
21	c-myc	c-myc	_	_	_	_	_	_	_
22	,	,	_	_	_	_	_	_	_
23	retinoblastoma	retinoblastoma	_	_	_	_	_	_	_
24	protein	protein	_	_	_	_	_	_	_
25	,	,	_	_	_	_	_	_	_
26	cyclin-dependent	cyclin-dependent	_	_	_	_	_	_	_
27	kinase	kinase	_	_	_	_	_	_	_
28	4	4	_	_	_	_	_	_	_
29	,	,	_	_	_	_	_	_	_
30	cyclin	cyclin	_	_	_	_	_	_	_
31	D1	d1	_	_	_	_	_	_	_
32	,	,	_	_	_	_	_	_	_
33	and	and	_	_	_	_	_	_	_
34	p53	p53	_	_	_	_	_	_	_
35	,	,	_	_	_	_	_	_	_
36	or	or	_	_	_	_	_	_	_
37	expression	expression	_	_	_	_	_	_	_
38	of	of	_	_	_	_	_	_	_
39	differentiation-related	differentiation-related	_	_	_	_	_	_	_
40	antigens	antigen	_	_	_	_	_	_	_
41	.	.	_	_	_	_	_	_	_

1	CONCLUSIONS	conclusions	_	_	_	_	_	_	_
2	:	:	_	_	_	_	_	_	_
3	Substantial	substantial	_	_	_	_	_	_	_
4	growth	growth	_	_	_	_	_	_	_
5	inhibition	inhibition	_	_	_	_	_	_	_
6	and	and	_	_	_	_	_	_	_
7	apoptosis	apoptosis	_	_	_	_	_	_	_
8	without	without	_	_	_	_	_	_	_
9	evidence	evidence	_	_	_	_	_	_	_
10	of	of	_	_	_	_	_	_	_
11	differentiation	differentiation	_	_	_	_	_	_	_
12	were	be	_	_	_	_	_	_	_
13	induced	induce	_	_	_	_	_	_	_
14	in	in	_	_	_	_	_	_	_
15	most	most	_	_	_	_	_	_	_
16	malignant	malignant	_	_	_	_	_	_	_
17	lymphocytic	lymphocytic	_	_	_	_	_	_	_
18	cells	cell	_	_	_	_	_	_	_
19	treated	treat	_	_	_	_	_	_	_
20	with	with	_	_	_	_	_	_	_
21	1-2	1-2	_	_	_	_	_	_	_
22	microM	microm	_	_	_	_	_	_	_
23	As2O3	as2o3	_	_	_	_	_	_	_
24	.	.	_	_	_	_	_	_	_

1	As2O3	As2O3	_	_	_	_	_	_	_
2	may	may	_	_	_	_	_	_	_
3	prove	prove	_	_	_	_	_	_	_
4	useful	useful	_	_	_	_	_	_	_
5	in	in	_	_	_	_	_	_	_
6	the	the	_	_	_	_	_	_	_
7	treatment	treatment	_	_	_	_	_	_	_
8	of	of	_	_	_	_	_	_	_
9	malignant	malignant	_	_	_	_	_	_	_
10	lymphoproliferative	lymphoproliferative	_	_	_	_	_	_	_
11	disorders	disorder	_	_	_	_	_	_	_
12	.	.	_	_	_	_	_	_	_

